BTK and B-cell chronic lymphocytic leukemia: The treatment of CLL has been fundamentally changed by the introduction of kinase inhibitors targeting B-cell receptor signaling kinases such as first generation Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib and the second generation more selective co-valent BTK inhibitor acalabrutinib [3].